Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
about
Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repairThe regulation and deregulation of Wnt signaling by PARK genes in health and diseaseEfficient and biologically relevant consensus strategy for Parkinson's disease gene prioritization.The importance of Wnt signalling for neurodegeneration in Parkinson's diseaseDopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's diseaseA Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotectionAltered transcription factor trafficking in oxidatively-stressed neuronal cells.Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease.α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons.The N-terminal region of Nurr1 (a.a 1-31) is essential for its efficient degradation by the ubiquitin proteasome pathway.NURR1 in Parkinson disease--from pathogenesis to therapeutic potential.Ligand Dependent Switch from RXR Homo- to RXR-NURR1 Heterodimerization.Retrograde Axonal Degeneration in Parkinson Disease.The Transcription Factor NURR1 Exerts Concentration-Dependent Effects on Target Genes Mediating Distinct Biological Processes.Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease.
P2860
Q26865502-ED1565E5-F823-4553-AF51-F6A9771F0E1FQ26991986-57E6E6D1-BFEA-4BF0-B864-BAA331FCDEECQ27304699-FBCDD16D-6C89-46C8-8A73-B9B4355BD6B2Q28115237-7697B5BB-352B-4BA4-B67D-C4CEA5FD117AQ28511558-6E0C1CE0-499B-404C-BFE3-2E8E74BBC5C3Q28589470-67D5DAC3-BDA0-4A54-B1AB-38149DC20E0AQ30419484-B0D16C5A-619E-4B2D-9D2A-974995A7A7ADQ30557555-FDBD37DD-AEF0-44EF-8B81-D3A8522FE91DQ34503671-8A50F49F-9678-40EF-AAEB-7AEB600D84FAQ34586538-13D854F0-5F9D-4E75-B2A3-0BF2C9A02B88Q35017493-4FA272FE-65B7-4676-9542-464FF90F11DFQ38686743-DD37749F-2646-427D-BB2D-7DF9A1B67883Q38785075-F398C083-757B-46B0-B98D-1686DFCDB164Q39932498-63284731-A626-4F91-B521-C56282DB10C5Q42291314-2C258996-F019-4FA0-BC7D-7AE7454D4468
P2860
Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
@ast
Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
@en
Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
@en-gb
Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
@nl
type
label
Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
@ast
Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
@en
Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
@en-gb
Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
@nl
prefLabel
Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
@ast
Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
@en
Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
@en-gb
Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
@nl
P2093
P2860
P921
P1433
P1476
Characterisation of a novel NR4A2 mutation in Parkinson's disease brain
@en
P2093
D S Latchman
J K J Diss
J L Holton
M M K Muqit
M R Cookson
M Van Der Brug
P2860
P356
10.1016/J.NEULET.2009.03.021
P407
P577
2009-06-26T00:00:00Z